Chiara Pircher
European Neuroendocrine Tumor Society(DE)Fondazione IRCCS Istituto Nazionale dei Tumori(IT)
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Cholangiocarcinoma and Gallbladder Cancer Studies, Renal cell carcinoma treatment, Gallbladder and Bile Duct Disorders
Most-Cited Works
- → Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial(2018)250 cited
- → NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer(2024)98 cited
- → Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial(2018)68 cited
- → A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma(2018)57 cited
- → A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)(2022)49 cited
- → Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma(2021)35 cited
- → Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients(2023)31 cited
- → Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy(2022)28 cited
- → Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial(2024)21 cited
- → COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study(2020)18 cited